rs121909112
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_001540.5(HSPB1):āc.418C>Gā(p.Arg140Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000242 in 1,240,538 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: not found (cov: 32)
Exomes š: 0.0000024 ( 0 hom. )
Consequence
HSPB1
NM_001540.5 missense
NM_001540.5 missense
Scores
11
7
1
Clinical Significance
Conservation
PhyloP100: 2.93
Genes affected
HSPB1 (HGNC:5246): (heat shock protein family B (small) member 1) This gene encodes a member of the small heat shock protein (HSP20) family of proteins. In response to environmental stress, the encoded protein translocates from the cytoplasm to the nucleus and functions as a molecular chaperone that promotes the correct folding of other proteins. This protein plays an important role in the differentiation of a wide variety of cell types. Expression of this gene is correlated with poor clinical outcome in multiple human cancers, and the encoded protein may promote cancer cell proliferation and metastasis, while protecting cancer cells from apoptosis. Mutations in this gene have been identified in human patients with Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 8 uncertain in NM_001540.5
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.992
PP5
Variant 7-76303855-C-G is Pathogenic according to our data. Variant chr7-76303855-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 7484.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-76303855-C-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HSPB1 | NM_001540.5 | c.418C>G | p.Arg140Gly | missense_variant | 2/3 | ENST00000248553.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HSPB1 | ENST00000248553.7 | c.418C>G | p.Arg140Gly | missense_variant | 2/3 | 1 | NM_001540.5 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 0.00000242 AC: 3AN: 1240538Hom.: 0 Cov.: 36 AF XY: 0.00000486 AC XY: 3AN XY: 617200
GnomAD4 exome
AF:
AC:
3
AN:
1240538
Hom.:
Cov.:
36
AF XY:
AC XY:
3
AN XY:
617200
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 13, 2020 | PS3, PS4_moderate, PM1, PM2, PP4 - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 28, 2023 | This variant has been identified in multiple unrelated individuals with clinical features associated with CMT or hereditary motor neuropathy. This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Assessment of experimental evidence suggests this variant results in abnormal protein function. (PMID: 23643870, 28595321) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 03, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 26, 2023 | Published functional studies demonstrate a damaging effect, including decreased chaperone-like activity and impaired mitochondrial function in motor neurons (Nefedova et al., 2013; Kalmar et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28000086, 26989944, 23643870, 27933579, 28389817, 15706088, 27816334, 26752306, 23379525, 28595321, 29547183, 32376792, 18832141, 28702508, 31561939) - |
Charcot-Marie-Tooth disease axonal type 2F Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 04, 2024 | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 140 of the HSPB1 protein (p.Arg140Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with distal vacuolar myopathy and motor neuropathy and Charcot-Marie-Tooth disease type 2 (CMT2) and distal hereditary motor neuropathy (dHMN) (PMID: 18832141, 27816334, 28702508). ClinVar contains an entry for this variant (Variation ID: 7484). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on HSPB1 protein function. Experimental studies have shown that this missense change affects HSPB1 function (PMID: 23643870, 28595321). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Aug 27, 2019 | A heterozygous missense variation in the exon 2 of the HSPB1 gene that results in the amino acid substitution of Glycine for Arginine at codon 140 was detected. The observed variant c.418C>G (p.Arg140Gly) has not been reported in 1000 genomes and ExAC databases. The in silico predictions of the variant are damaging by SIFT, LRT and MutationTaster2. The observed variant has previously been reported in patients affected with Charcot-Marie-Tooth disease type 2 (Holden et al 2008 Neurology). Furthermore, functional studies have shown that the said variant affects the quaternary structure and decreases the chaperon like activity of the protein (Nefedova et al 2013 Biochimie). In summary, the said variant meets our criteria to be classified as pathogenic. - |
Charcot-Marie-Tooth disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, London Health Sciences Centre | - | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 08, 2020 | The p.R140G variant (also known as c.418C>G), located in coding exon 2 of the HSPB1 gene, results from a C to G substitution at nucleotide position 418. The arginine at codon 140 is replaced by glycine, an amino acid with dissimilar properties. This alteration has been described in multiple unrelated individuals diagnosed with distal hereditary motor neuropathy (dHMN), Charcot-Marie-Tooth type 2 (CMT2), and a syndrome overlapping both dHMN/CMT2 clinical symptoms (Ghodasara MK et al. Neurol India;66:528-529; Houlden H et al. Neurology, 2008 Nov;71:1660-8; Luigetti M et al. Clin Neurol Neurosurg, 2016 May;144:67-71; Rossor AM et al. Neuromuscul Disord, 2017 Jan;27:50-56; Tanabe H et al. J Peripher Nerv Syst, 2018 03;23:40-48). A patient who presented with vacuolar myopathy and axonal motor neuropathy was described as homozygous for this alteration. Parents were mildly affected upon clinical examination in their 80s (Bugiardini E et al. Neurol Genet, 2017 Aug;3:e168). Functional studies suggest this alteration impairs mitochondrial function and results in a reduction of chaperone-like activity (Kalmar B et al. Hum Mol Genet 2017 Sep; 26:3313-3326; Nefedova V et al. Biochimie 2013 Aug;95:1582-1592). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Neuronopathy, distal hereditary motor, type 2B Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 18, 2008 | - - |
HSPB1-related axonal neuropathies Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 12, 2021 | The HSPB1 c.418C>G (p.Arg140Gly) variant is a missense variant. Across a selection of the available literature, the p.Arg140Gly variant has been identified in a heterozygous state in seven index cases from at least three diverse populations with late onset Charcot-Marie-Tooth disease or hereditary motor neuronopathy (Houlden et al. 2008; Luigetti et al. 2016; Tanabe et al. 2018; Peddareddygari et al. 2019). The p.Arg140Gly was noted to segregate with disease in seven affected family members across two generations in a large pedigree originating from the Gujarat region of India (Peddareddygari et al. 2019). The p.Arg140Gly variant has been reported in at least four additional families from this region, leading to speculation that it may be a founder variant in this group (Rosser et al 2017; Peddareddygari et al. 2019). The p.Arg140Gly variant was also identified in a homozygous state in a 57-year-old female with distal vacuolar myopathy and motor neuropathy, first manifesting at 20 years of age (Bugiardini et al. 2017). Clinical examination of the proband's parents, both in their eighties, revealed mild distal weakness in the upper and lower limbs with areflexia, demonstrating the clinical variability associated with this variant. The p.Arg140Gly variant is not found in version 2.1.1 or version 3.1.1 of the Genome Aggregation Database despite its location in a region of good sequence coverage, which suggests the variant is rare. The Arg140 residue is located within the beta 7 strand of a-crystallin domain of HspB1 protein and predicted to disrupt the quaternary structure of HspB1, decreasing its chaperone like activity (Nefedova et al. 2013). Experiments expressing the variant in a heterologous state using a lentiviral system in primary cultured mouse motor neurons showed that, in this model, p.Arg140Gly reduced the speed and altered the pausing frequency of retrograde axonal mitochondrial transport, leading to an increased vulnerability of these cells to oxidative stress (Kalmar et al. 2017). Based on the available evidence, the p.Arg140Gly variant is classified as pathogenic for HSPB1-related axonal neuropathies. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H
MutationTaster
Benign
A;A
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
B
Vest4
MutPred
Loss of methylation at K141 (P = 0.0471);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at